# A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

> **NCT06816264** · PHASE2 · COMPLETED · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Treatment of Lipoprotein Disorder

## Interventions

- **DRUG:** HRS-5346
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06816264
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-18
- **Primary completion:** 2025-09-29
- **Final completion:** 2025-09-29
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816264, "A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06816264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*